Intellia Therapeutics finds itself navigating turbulent waters, with its stock price hitting fresh lows as a combination of clinical setbacks and insider sel ...

Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

A recent study in the journal PNAS from the lab of Julie Overbaugh reveals a previously unknown antiviral function of a gene involved in the immune defense against Zika virus that has implications for ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...